Medical Properties Trust
MPT
3.23
-0.07
-2.12%
Medical Properties Trust
US · MPT
#2789 by market cap
Listed 1970
3.23
-0.07
-2.12%
Live - 5344 symbols - heartbeat 538s ago
· 2026-10-08 08:27
Pre-market
3.23
0.00%
After-hours
3.24
+0.31%
- Market cap
- 1.93B
- P/E (TTM)i
- -64.60
- P/Bi
- 0.43
- EPSi
- -0.46
- Div yieldi
- 10.84%
- 52W posi
- 1%
Reader sentiment
Are you bullish or bearish on MPT?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -0.04, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -2.36% YoY
Margins
- Gross margin
- 96.25%
- Operating margin
- 55.53%
- Net margin
- -28.59%
Key ratios & quality
- Enterprise valuei
- 11.09B
- Altman Z-Scorei
- -0.04
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 784.52M | 854.20M | 1.25B | 1.54B | 1.54B | 871.80M | 995.55M | 972.02M |
| Gross profit | 775.29M | 830.21M | 1.22B | 1.51B | 1.50B | 830.23M | 968.29M | 935.61M |
| Selling & admin expenses | 81.00M | 96.41M | 131.66M | 145.64M | 160.49M | 145.59M | 133.79M | 130.43M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 561.20M | 581.48M | 828.44M | 1.04B | 1.00B | 81.28M | 386.85M | 539.78M |
| Pretax profit | 1.02B | 373.78M | 463.33M | 730.89M | 959.72M | -686.77M | -2.36B | -237.32M |
| Tax | 927.00K | -2.62M | 31.06M | 73.95M | 55.90M | -130.68M | 44.10M | 38.62M |
| Net profit | 1.02B | 376.40M | 432.27M | 656.94M | 903.82M | -556.09M | -2.41B | -275.94M |
| Basic EPS | 3 | 1 | 1 | 1 | 2 | -1 | -4 | 0 |
| Diluted EPS | 2.76 | 0.87 | 0.81 | 1.11 | 1.50 | -0.93 | -4.02 | -0.46 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 223.80M | 240.36M | 237.52M | 270.34M | 252.07M | 259.28M |
| Gross profit | 216.76M | 229.50M | 228.53M | 260.82M | 242.13M | 248.08M |
| Selling & admin expenses | 41.91M | 26.20M | 37.73M | 24.59M | 32.21M | 34.77M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 110.28M | 136.58M | 123.80M | 169.11M | 140.20M | 143.86M |
| Pretax profit | -108.58M | -88.27M | -66.58M | 26.10M | 285.00K | 7.79M |
| Tax | 9.44M | 9.80M | 10.87M | 8.51M | -32.82M | 10.08M |
| Net profit | -118.02M | -98.07M | -77.45M | 17.60M | 33.11M | -2.29M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.20 | -0.16 | -0.13 | 0.03 | 0.05 | -0.01 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 1.50B | 2.46B | 2.03B | 1.41B | 1.72B | 1.40B | 1.31B | 1.82B |
| Cash & ST investments | 820.87M | 1.46B | 549.88M | 459.23M | 235.67M | 250.02M | 332.34M | 540.86M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 8.84B | 14.47B | 16.83B | 20.52B | 19.66B | 18.30B | 14.29B | 15.00B |
| Total current liabilities | 245.85M | 307.59M | 640.33M | 2.23B | 1.58B | 1.96B | 845.38M | 1.21B |
| Short-term debt | 28.06M | -- | 165.41M | 1.60B | 929.58M | 1.51B | 361.73M | 638.06M |
| Long-term debt | 4.01B | 7.02B | 8.70B | 9.68B | 9.34B | 8.55B | 8.49B | 9.06B |
| Total liabilities | 4,282,705,000.00 | 7,439,177,000.00 | 9,485,157,000.00 | 12,074,130,000.00 | 11,063,593,000.00 | 10,670,979,000.00 | 9,460,811,000.00 | 10,394,526,000.00 |
| Total equity | 4.56B | 7.03B | 7.34B | 8.45B | 8.59B | 7.63B | 4.83B | 4.61B |
| Retained earnings | 162.77M | 83.01M | -71.41M | -87.69M | 116.29M | -971.81M | -3.66B | -4.14B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.58B | 1.51B | 1.52B | 1.82B | 1.59B | 1.63B |
| Cash & ST investments | 673.48M | 509.83M | 396.58M | 540.86M | 425.00M | 396.56M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 14.85B | 15.15B | 14.92B | 15.00B | 14.76B | 14.75B |
| Total current liabilities | 1.12B | 1.07B | 1.07B | 1.21B | 1.12B | 1.17B |
| Short-term debt | 643.16M | 553.44M | 567.63M | 638.06M | 665.58M | 718.54M |
| Long-term debt | 8.82B | 9.10B | 9.05B | 9.06B | 9.00B | 8.99B |
| Total liabilities | 10,091,802,000.00 | 10,316,618,000.00 | 10,262,832,000.00 | 10,394,526,000.00 | 10,216,918,000.00 | 10,247,837,000.00 |
| Total equity | 4.76B | 4.83B | 4.66B | 4.61B | 4.55B | 4.50B |
| Retained earnings | -3.83B | -3.97B | -4.10B | -4.14B | -4.16B | -4.21B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 449.09M | 494.12M | 617.64M | 811.66M | 739.01M | 505.79M | 245.48M | 230.77M |
| Depreciation & amortization | 141.49M | 156.58M | 275.95M | 333.78M | 345.58M | 616.13M | 453.75M | 272.82M |
| Free cash flow | 449.09M | 494.12M | 617.64M | 811.66M | 739.01M | 505.79M | 245.48M | 230.77M |
| Dividends paid | -363.91M | -411.70M | -567.97M | -643.47M | -698.54M | -615.39M | -321.08M | -193.26M |
| Stock buybacks / issuance | 94.24M | 2.53B | 411.10M | 1.05B | -17.94M | 0 | 0 | -23.44M |
| Ending cash balance | 822.43M | 1.47B | 556.37M | 461.88M | 241.54M | 255.95M | 335.17M | 544.00M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 384.00K | 51.75M | 18.57M | 160.06M | -14.26M | 62.44M |
| Depreciation & amortization | 65.43M | 68.24M | 69.48M | 69.67M | 73.35M | 73.63M |
| Free cash flow | 384.00K | 51.75M | 18.57M | 160.06M | -14.26M | 62.44M |
| Dividends paid | -48.16M | -48.38M | -48.29M | -48.42M | -55.35M | -54.26M |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 676.49M | 512.91M | 399.63M | 544.00M | 427.95M | 399.43M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 24.30 | 6.43 | 6.01 | 8.32 | 10.60 | -6.88 | -38.69 | -5.89 |
| ROA %i | 11.38 | 3.19 | 2.76 | 3.51 | 4.49 | -2.94 | -14.79 | -1.90 |
| ROIC %i | 14.26 | 3.27 | 2.81 | 3.62 | 4.64 | -3.03 | -15.23 | -1.97 |
| 5-year avg ROE %i | 10.52 | 11.07 | 10.67 | 10.65 | 11.14 | 4.89 | -4.14 | -6.52 |
| EBIT margin %i | 158.40 | 68.07 | 66.32 | 67.24 | 65.05 | 9.32 | 38.86 | 55.53 |
| FCF / sales %i | 57.24 | 57.85 | 49.44 | 52.55 | 47.90 | 58.02 | 24.66 | 23.74 |
| Current ratioi | 6.11 | 8.01 | 3.17 | 0.63 | 1.09 | 0.71 | 1.55 | 1.51 |
| Quick ratioi | 5.86 | 7.71 | 3.04 | 0.59 | 0.90 | 0.62 | 1.39 | 1.35 |
| Debt / assetsi | 45.96 | 49.29 | 53.54 | 55.75 | 52.98 | 55.84 | 62.80 | 65.50 |
| LT debt / equityi | 88.78 | 101.47 | 120.53 | 116.60 | 110.38 | 114.08 | 178.27 | 199.47 |
| Interest coveragei | 5.57 | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | 21.09 | 16.44 | 21.02 | 25.34 | 21.78 | -11.30 | -13.62 | -14.27 |
| Net income CAGR (3Y) %i | 93.84 | 18.52 | 14.19 | -13.59 | 34.05 | -- | -- | -- |
| FCF CAGR (3Y) %i | 29.46 | 23.26 | 19.47 | 21.81 | 14.36 | -6.44 | -32.88 | -32.16 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -28.86 | -25.97 | -14.02 | -5.89 | -2.73 | -0.68 |
| ROA %i | -10.29 | -9.13 | -4.69 | -1.90 | -0.86 | -0.21 |
| ROIC %i | -10.55 | -9.43 | -4.85 | -1.97 | -0.88 | -0.22 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 121.28 | 151.32 | 229.92 | 55.53 | 66.60 | 75.33 |
| FCF / sales %i | 18.09 | 20.40 | 15.79 | 23.74 | 21.61 | 22.25 |
| Current ratioi | 1.41 | 1.41 | 1.43 | 1.51 | 1.42 | 1.40 |
| Quick ratioi | 1.41 | 1.41 | 1.43 | 1.35 | 1.42 | 1.40 |
| Debt / assetsi | 64.73 | 64.67 | 65.43 | 65.50 | 66.15 | 66.46 |
| LT debt / equityi | 188.44 | 191.30 | 197.35 | 199.47 | 200.22 | 201.88 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Acquisition and development of healthcare facilities100.00%
Quote time 2026-10-08 08:27:14 · For reference only, not investment advice and not tailored to your situation.